Whitepapers

Whitepaper Dec 9, 2021

Fostering Data Generation to Build the Value Story

Whitepaper Nov 30, 2021

The Value of Insights

Whitepaper Nov 30, 2021

Estimating Comparative Effectiveness Using Single-Arm Trials: Overcoming Additional Challenges in the Tumour-Agnostic Space

Whitepaper Sep 24, 2021

A Subscription to Innovation: Could NHS England’s Novel Frameworks for Antimicrobials Be the Future of HTA?

Whitepaper Sep 3, 2021

Heterogeneity & Generalizability: The Core Difficulties in Estimating the Effectiveness of Tumour-Agnostic Drugs in Practice

Whitepaper Aug 9, 2021

Understanding the Payer Mindset Throughout the Brand Journey

Whitepaper Aug 4, 2021

An Introduction to Planning for HTA for Tumour-Agnostic Cancer Drugs

Whitepaper May 19, 2021

Are There Only 10 Commercial Strategies in Pharma?

Whitepaper May 13, 2021

Connecting the Dots: Harnessing Real World Data in Healthcare Decision Making

Whitepaper Apr 29, 2021

Next Wave Anti-Cancer Therapies: Part 1

Whitepaper Apr 26, 2021

Five Learnings Manufacturers Should Take from the Latest NICE Guidance on Survival Modelling

Whitepaper Mar 19, 2021

Navigating the Post-COVID Landscape

Whitepaper Jan 29, 2021

Accelerating Access to New Innovative Treatments: Lessons From COVID-19

Whitepaper Jan 28, 2021

How Are Medical Affairs Organizations Proving Their Value?

Whitepaper Nov 27, 2020

How the Latest NICE Methods Consultation Could Impact Your Evidence Generation Strategy

Whitepaper Oct 30, 2020

‘Excel cannot complete this task’: Drawing parallels between UK Test and Trace and health economic models

1 … 4 5 6 7